Chronic lymphocytic leukemia (CLL) is a neoplastic disease of mature B cells that express a functional immunoglobulin (Ig) B-cell receptor (Ig-BCR) on the cell surface.1 The Ig-BCR includes the binding site (idiotype) for the epitope of cognate antigen, which results from the stochastic and productive Ig variable genes rearrangement and possible somatic hypermutation. Individual B-cell clones differ from one another because of the diverse amino acid sequences within the idiotype of the expressed Ig-BCR,2 so that the epitopic specificity is shared in a given clonal B-cell population.
Several studies have recently highlighted two peculiar characteristics that distinguish CLL among other mature B-cell malignancies. First, the Ig-BCR repertoire of CLL is biased, as it is restricted toward the preferential usage of certain Ig heavy- (IgVH) and light (IgVκ/λ) -chain variable genes,3, 4 and unusually similar, stereotyped heavy-chain complementarity determining region 3 (VH CDR3) amino acid sequences.5 The skewed Ig-BCR could be owing to an Ig-BCR-driven selection mechanism initiated by specific antigens that promote the expansion and possibly the maintenance of the cognate CLL clone.6 Consistent with this hypothesis, several studies have demonstrated the reactivity of CLL Ig-BCR against foreign antigens, self-antigens, peptides and intrinsic IgVH motif.7 Second, CLL is not always a monoclonal disorder, as two or multiple CLL clones have been found in 2–5% of CLL patients.8, 9 Furthermore, the monoclonal B-lymphocytosis precursor state, which precedes the clinically relevant leukemic phase in virtually all CLL patients, sometimes involves multiple B-cell clones.10
It is still unknown whether two or more CLL clonotypes within the same patient potentially associate with the same antigenic reactivity, or alternatively arise as stochastic and antigen-independent events, fostered by the accumulation of oncogenic abnormalities in the preleukemic state. To answer this question, here we have characterized the epitope recognition profiles of CLL clonotypes by coupling the genetic analysis of Ig variable genes and the epitopic reactivity at single-cell level.
We isolated single CD5+ B cells from peripheral blood of six newly diagnosed untreated CLL patients, randomly referred to the Medical Oncology Unit—University Magna Graecia of Catanzaro. CLL patients displayed the typical CLL immunophenotype, with no evidence of separate/aberrant B-cell populations (Supplementary Table S1). We determined the VHDJH and VLJL complementary DNA (cDNA) sequence of at least 20 single leukemic cells per patient (Supplementary Table S2). All cDNA sequences showed a productive rearrangement at the heavy- and light-gene loci. In particular, we detected single and distinct VHDJH and VLDL rearrangements in CLL#1, CLL#2 and CLL#3, indicating the presence of a single clonotype (Table 1, Supplementary Table S2). Differently, CLL#4, CLL#5 and CLL#6 exhibited two different VHDJH rearrangements, each of them pairing with a unique and distinct VLJL rearrangement, indicating the coexistence of two clonotypes (Table 1, Supplementary Table S2). The coexistence of two clonotypes in CLL#4, CLL#5 and CLL#6 was confirmed by the heteroduplex analysis and sequencing of VHDJH and VLJL rearrangements amplified from the bulk CLL cells (Supplementary Figure S1). Of note, the Vκ usage of clonotypes CLL5-1, CLL6-1 and CLL6-2 were univocally assigned to Vκ genes of the distal cluster, which is evocative of receptor editing.
The analysis of nucleotide differences among the VH sequences of the same clonotype showed a variable degree of base-pair substitutions (Supplementary Table S3). Despite the intraclonal diversity of the VH region, each clonotype showed either an identical or two quasi-identical VH CDR3 amino acid sequences (Table 1 and Supplementary Table S3). By comparing the VH CDR3 amino acid sequence of clonotypes with a data set of stereotypic Ig-BCRs,5 CLL6-2 was found to be a member of the major subset 16, whereas other clonotypes did not fall within the stereotypic subsets (Table 1).
Next, we aimed to identify peptide mimetics of the natural epitope (hereafter, referred as mimotopes) that bound to the Ig-BCR of CLL clonotypes. To this end, we produced monoclonal antibodies IgG1 (mIgCLLs) that carried the VHDJH and VLJL rearrangements of CLL clonotypes linked to an IgHCγ1, or IgLCκ/λ segment, as described11 (Table 1, Supplementary Figure S2). The mIgCLLs were used as baits for screening a constrained (CX7C) random phage-displayed peptide library,12 which resulted in the isolation of at least 25 phage clones for each mIgCLL bait (Supplementary Table S4). We observed a considerable difference of enzyme-linked immunosorbent assay (ELISA)-binding reactivity among the phage clones isolated through the same mIgCLL (Supplementary Figure S3). As mimotopes are equally distributed among phage particle (five copies per phage), we assumed that the differences in the binding affinity of distinct mimotopes to the same mIgCLL might account for the differences in the ELISA-binding reactivity.
Hence, we synthesized a number of peptides corresponding to the phage-displayed mimotopes that had shown the highest binding affinity toward the cognate mIgCLL (Table 1). Synthetic mimotopes bound in a dose-dependent manner to the cognate mIgCLL, whereas tested negative for control human polyclonal Igs (Supplementary Figure S4), demonstrating that the selected mimotopes maintained the mIgCLL-binding ability out of the phage context. The equilibrium constant KD of synthetic mimotope binding to the cognate mIgCLL was in the nanomolar range, as estimated by the Scatchard plot analysis (Table 1).
All mimotopes bound to the corresponding CLL cells, and not to normal B (sIg+/CD19+) or non-B cells (sIgG−/CD19−) isolated from the peripheral blood of a pool of healthy donors, as shown by the fuorescence-activated cell sorting analysis (Figure 1a). The mimotopes binding to B-CLL cells was competed in a dose-dependent manner by soluble cognate mIgCLLs and not by polyclonal human IgG1 (Supplementary Figure S5). Moreover, mimotopes colocalized with the sIg-BCR on the surface of the cognate B-CLLs, as shown by the confocal microscopy (Figure 1b). Overall, these data confirmed that the mimotope binding to the corresponding B-CLL cells was specifically achieved through direct interaction with the sIg-BCR, thus validating the selected mimotopes as truly representative of the epitopic reactivity of the original CLL cells.
Then, we performed a systematic characterization of the epitopic reactivity of CLL clonotypes by probing the binding of individual mIgCLLs to all selected mimotopes by ELISA. Each mIgCLL was able to bind not only to its cognate mimotope, but also to distinct mimotopes of others mIgCLLs (Figure 1c). These results highlighted a certain degree of common epitopic reactivity among the mIgCLLs, as previously reported by others.13, 14
A first level of common reactivity regarded the mIgCLLs derived from the same patient that invariably shared the epitopic reactivity, regardless they were classified as distinct clonotypes. In particular, the mIgCLLs with quasi-identical VH CDR3, which were derived from patients harboring a unique clonotype (mIgCLL2-1 and mIgCLL2-2 from patient CLL#2; mIgCLL3-1 and mIgCLL3-2 from patient CLL#3), equally bound to the two selected mimotopes (pCLL2-1 and pCLL2-2 for patient CLL#2; pCLL3-1 and pCLL3-2 for patient CLL#3), thus indicating that the small differences in their VH CDR3 did not affect their binding affinity (Figure 1c). The mIgCLLs derived from patients harboring two different clonotypes (mIgCLL4-1 and mIgCLL4-2; mIgCLL5-1 and mIgCLL5-2; mIgCLL6-1 and mIgCLL6-2) also showed common epitopic reactivity, even though with different ELISA reactivity. Thus, the diverse VH CDR3 pattern of distinct CLL clonotypes harbored by the same patient did not prevent the binding to a common set of mimotopes.
A second level of shared epitopic reactivity was observed for some mIgCLLs derived from different patients. In particular, the mIgCLLs derived from patients CLL#1, CLL#2 and CLL#6 recognized the same subset of mimotopes (pCLL1, pCLL2-1, pCLL2-2, pCLL6-1 and pCLL6-2; Figure 1c). The mIgCLL4-2 also shared a similar ELISA-binding profile, except for the binding to pCLL1-2.
The clonotypic mIgCLL1, mIgCLL2, mIgCLL4-2, mIgCLL6-1 and mIgCLL6-2 did not show any obvious similarity in the VH CDR3 primary structure, or a preferential usage of VH and VL regions that would account for the common binding to the same subset of mimotopes. Hence, their shared epitopic reactivity should lie on structural motifs of the whole VH and VL regions, which will require further investigation.
Overall, these data demonstrated that (a) mIgCLLs derived from independent B-cell clones of the same CLL patient shared the epitopic reactivity and (b) a subset of CLLs exhibited some degree of common epitope reactivity.
Our results confirmed recent findings on the appearance of two or more independent B-CLL clones within the same patient.8, 9, 10 Importantly, we document for the first time that the Ig-BCRs of unrelated clonotypes in the same CLL patient may recognize common epitopes, thus revealing a striking homogeneity, grounded on epitopic reactivity, that was unpredictable from the molecular features of the Ig-BCR, including the CDR3 composition and length. The coexistence within the same patient of two unrelated CLLs clonotypes associated with the same epitopic reactivity reinforces the key role of antigenic selection in CLL pathogenesis and demand a more exhaustive understanding of the biology of this disease based on epitopic reactivity.
References
Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S . From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37–50.
Hershberg U, Luning Prak ET . The analysis of clonal expansions in normal and autoimmune B cell repertoires. Philos Trans R Soc Lond B Biol Sci 2015; 370: 1–16.
Ghiotto F, Fais F, Valetto A, Albesiano E, Hashimoto S, Dono M et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004; 113: 1008–1016.
Messmer BT, Albesiano E, Efremov DG, Ghiotto F, Allen SL, Kolitz J et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200: 519–525.
Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012; 119: 4467–4475.
Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G . B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011; 118: 4313–4320.
Sutton LA, Rosenquist R . The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol 2015; 34: 22–35.
Plevova K, Francova HS, Burckova K, Brychtova Y, Doubek M, Pavlova S et al. Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. Haematologica 2014; 99: 329–338.
Sanchez ML, Almeida J, Gonzalez D, Gonzalez M, Garcia-Marcos MA, Balanzategui A et al. Incidence and clinicobiologic characteristics of leukemic B-cell chronic lymphoproliferative disorders with more than one B-cell clone. Blood 2003; 102: 2994–3002.
Klinger M, Zheng J, Elenitoba-Johnson KS, Perkins SL, Faham M, Bahler DW . Next-generation IgVH sequencing CLL-like monoclonal B-cell lymphocytosis reveals frequent oligoclonality and ongoing hypermutation. Leukemia 2015; 30: 1055–1061.
Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H . Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 2008; 329: 112–124.
Palmieri C, Falcone C, Iaccino E, Tuccillo FM, Gaspari M, Trimboli F et al. In vivo targeting and growth inhibition of the A20 murine B-cell lymphoma by an idiotype-specific peptide binder. Blood 2010; 116: 226–238.
Binder M, Muller F, Jackst A, Lechenne B, Pantic M, Bacher U et al. B-cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia. Cancer 2011; 117: 1891–1900.
Seiler T, Woelfle M, Yancopoulos S, Catera R, Li W, Hatzi K et al. Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. Blood 2009; 114: 3615–3624.
Acknowledgements
This work was supported by Ministero della Salute Grants GR-2009-1606801 (to CP) and RF-2010-2306943 (to GS), and Ministero dell’Istruzione, dell’Università e della Ricerca Grant POR CALABRIA FSE 2007/2013 (to GS), International Agency for Research on Cancer (AIRC) Grant IG-2009- 9411 (to GS), and COFIN-MIUR (to GS and IQ). We thank Dr Michel Nussenzweig (The Rockefeller University Hospital, NY, USA) for plasmids expressing the Igγ1, Igk or Igλ constant regions.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
About this article
Cite this article
Mimmi, S., Vecchio, E., Iaccino, E. et al. Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients. Leukemia 30, 2419–2422 (2016). https://doi.org/10.1038/leu.2016.245
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.245
This article is cited by
-
Detection of chronic lymphocytic leukemia subpopulations in peripheral blood by phage ligands of tumor immunoglobulin B cell receptors
Leukemia (2021)
-
Unconventional secretion of α-Crystallin B requires the Autophagic pathway and is controlled by phosphorylation of its serine 59 residue
Scientific Reports (2019)
-
The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia
Leukemia (2019)
-
Activation of NF-κB in B cell receptor signaling through Bruton’s tyrosine kinase-dependent phosphorylation of IκB-α
Journal of Molecular Medicine (2019)
-
Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL
Leukemia (2018)